ARS Pharmaceuticals, Inc. SPRY R2K
Healthcare · Biotechnology · United States
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
READ MORE ›$9.07
-37.14% 1Y
Market & Price
Market Cap
$900.68M
Current Price
$9.07
High / Low (52W)
$18.35 / $6.73
Beta
0.80
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$1.15
Price to Book
7.88
P/S
9.10
EV/EBITDA
-4.33
Dividend Yield
-
Profitability & Returns
ROCE
-58.50%
ROE
-136.40%
ROA
-41.15%
Profit Margin
-
Op Margin
-
EPS (Latest Qtr)
$-0.61
EPS (TTM)
$-2.00
Balance Sheet & Liquidity
Debt/Equity
2.79
Quick Ratio
4.64
Current Ratio
4.94
Debt
$171.20M
Total Assets
$327.65M
Current Assets
$284.90M
Working Capital
$245.75M
Ownership
Promoter Holding
16.29%
Chg in Prom Hold
-
FII / Inst Holding
95.48%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$870.91M
Total Revenue (TTM)
$98.99M
EBITDA
$-200.93M
Free Cash Flow
$-98.28M
Operating Cash Flow
$-175.07M
Shares Outstanding
99.30M
Gross Margin
59.41%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
300.09%
Profit 5Y
-131.30%
Revenue (YoY)
184.50%
Earnings (YoY)
-
PROS
- Compounding revenue at 300.1% over 5 years.
CONS
- Earnings shrank at -131.3% CAGR over 5 years.
- Trading 50.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SPRY ARS Pharmaceuticals, Inc. R2K | 9.07 | - | $900.68M | - | -58.50% | -136.40% | 300.09% | -131.30% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 663.00K | 464.00K | 189.00K | 20.00K | 10.00K | 0 | 0 | 500.00K | - | - | 7.97M | 15.72M | 32.50M | 28.09M | 22.68M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.09M | 4.98M | 8.19M | 6.15M | 6.29M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.88M | 10.73M | 24.31M | 21.93M | 16.39M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 44.06M | 58.35M | 77.50M | 63.40M | 76.54M |
| Operating Income | -5.24M | -6.46M | -8.11M | -18.89M | -24.51M | -22.68M | -7.10M | -6.34M | -6.63M | -18.71M | -20.60M | -17.98M | -13.19M | -15.34M | - | - | -37.18M | -47.61M | -53.19M | -41.47M | -60.15M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -33.94M | -47.61M | -53.19M | -30.80M | -58.18M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 2.44M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -33.94M | -44.88M | -51.15M | -41.40M | -60.62M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -5.28M | -6.47M | -8.12M | -18.87M | -24.50M | -22.66M | -7.25M | -6.42M | -6.58M | -14.96M | -17.37M | -14.87M | -10.29M | -12.52M | - | - | -33.94M | -44.88M | -51.15M | -41.32M | -60.62M |
| Diluted EPS | - | - | - | - | - | -0.65 | -0.24 | -0.21 | -0.21 | -0.16 | -0.18 | -0.16 | -0.11 | -0.13 | -0.20 | - | -0.35 | -0.46 | -0.52 | - | -0.61 |
| R&D Expense | 4.41M | 5.13M | 6.20M | 12.24M | 17.75M | 15.64M | 5.42M | 4.35M | 3.89M | 6.55M | 7.31M | 3.00M | 5.23M | 6.90M | 4.42M | - | 2.95M | 4.04M | 2.75M | - | 4.34M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 1.32M | 30.00K | 89.15M | 84.28M |
| Cost of Revenue | - | - | - | 0 | 977.00K | 20.42M |
| Gross Profit | - | - | - | 30.00K | 88.17M | 63.85M |
| Operating Expenses | - | - | 36.83M | 67.55M | 91.25M | 243.30M |
| Operating Income | -32.92M | - | -35.52M | -67.52M | -3.08M | -179.45M |
| EBITDA | - | - | -35.20M | -67.52M | 8.29M | -168.78M |
| Interest Expense | - | - | - | - | 0 | 2.60M |
| Pretax Income | - | - | -34.68M | -54.37M | 8.29M | -171.38M |
| Tax Provision | - | - | - | 0 | 288.00K | -80.00K |
| Net Income | -32.95M | - | -34.68M | -54.37M | 8.00M | -171.30M |
| Diluted EPS | - | -0.22 | -0.87 | -0.57 | 0.08 | - |
| R&D Expense | 24.58M | 20.27M | 18.38M | 20.27M | 19.58M | 13.18M |
Compounded Sales Growth
| 5 Years: | 300.09% |
| 1 Year: | 184.50% |
Compounded Profit Growth
| 5 Years: | -131.30% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -37.14% |
| 6 Months: | -2.26% |
| 3 Months: | -2.26% |
| 1 Month: | +15.69% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 394.80M | - | 281.44M | 233.19M | 351.15M | 327.65M |
| Current Assets | - | - | - | 277.70M | 231.73M | 334.30M | 284.90M |
| Cash & Equivalents | - | 386.57M | - | 210.52M | 70.97M | 50.82M | 41.32M |
| Inventory | - | - | - | - | 0 | 5.21M | 8.37M |
| Receivables | - | - | 0 | - | 0 | 8.18M | 25.35M |
| Total Liabilities | - | 11.93M | - | 8.55M | 2.43M | 94.36M | 213.39M |
| Current Liabilities | - | 9.60M | - | 5.44M | 2.39M | 23.44M | 39.15M |
| Long Term Debt | - | - | 4.93M | - | - | - | 96.37M |
| Total Debt | - | - | - | 481.00K | 274.00K | 42.00K | 96.37M |
| Total Equity | -58.78M | -14.05M | - | 272.89M | 230.76M | 256.80M | 114.26M |
| Shares Outstanding | - | - | - | 93.94M | 96.41M | 97.95M | 99.29M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -31.20M | - | -40.08M | -59.27M | 13.55M | -170.87M |
| Investing Cash Flow | -917.00K | - | -199.00K | -87.18M | -106.10M | 56.77M |
| Financing Cash Flow | 408.51M | - | 190.73M | 6.90M | 72.40M | 104.60M |
| Capital Expenditure | -917.00K | - | -199.00K | -175.00K | -563.00K | -339.00K |
| Free Cash Flow | -32.11M | - | -40.28M | -59.44M | 12.98M | -171.21M |
| Net Change in Cash | - | - | 150.46M | -139.55M | -20.15M | -9.50M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 100.0% | 98.9% | 75.8% |
| Operating Margin % | - | - | -2,698.8% | -225,066.7% | -3.5% | -212.9% |
| Net Margin % | - | - | -2,635.4% | -181,216.7% | 9.0% | -203.3% |
| ROE % | 234.5% | - | -12.7% | -23.6% | 3.1% | -149.9% |
| ROCE % | -8.5% | - | -12.9% | -29.3% | -0.9% | -62.2% |
Shareholding Pattern
Insiders
16.29%
Institutions
95.48%
Public Float
114.07%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 10.94% | 10.86M | $98.51M |
| 2 | Orbimed Advisors LLC. | 8.35% | 8.29M | $75.18M |
| 3 | Rubric Capital Management LP | 8.06% | 8.00M | $72.56M |
| 4 | Deerfield Management Company, L.P | 7.56% | 7.50M | $68.06M |
| 5 | Millennium Management Llc | 6.02% | 5.98M | $54.27M |
| 6 | Blackrock Inc. | 5.05% | 5.01M | $45.46M |
| 7 | Aberdeen Group plc | 4.14% | 4.11M | $37.31M |
| 8 | SR One Capital Management, LP | 4.04% | 4.01M | $36.40M |
| 9 | State Street Corporation | 3.67% | 3.64M | $33.06M |
| 10 | Franklin Resources, Inc. | 3.30% | 3.28M | $29.74M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SPRY
No recent headlines available.